Profile data is unavailable for this security.
About the company
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
- Revenue in HKD (TTM)6.47bn
- Net income in HKD1.37bn
- Incorporated2004
- Employees5.80k
- LocationSSY Group LtdRooms 4902-03, 49th Floor, Central Plaza18 Harbour RoadWanchai Hong KongHKG
- Phone+852 26880869
- Fax+852 27873338
- Websitehttp://www.ssygroup.com.hk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies Co Ltd | 7.57bn | 716.19m | 6.19bn | 4.01k | 8.64 | 0.7922 | 4.32 | 0.8174 | 0.5592 | 0.5592 | 5.91 | 6.10 | 0.5026 | 0.9881 | 5.22 | 1,845,461.00 | 7.42 | 7.68 | 11.69 | 12.32 | 40.97 | 43.50 | 14.76 | 16.11 | 2.30 | -- | 0.1968 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
| Beijing Tong Ren Tang Chinese Medicine | 1.38bn | 494.14m | 6.29bn | 779.00 | 12.74 | 1.65 | 10.18 | 4.57 | 0.5903 | 0.5903 | 1.64 | 4.55 | 0.3284 | 0.3554 | 3.62 | 1,725,133.00 | 12.72 | 16.71 | 14.09 | 18.75 | 72.06 | 69.88 | 38.72 | 40.72 | 9.55 | -- | 0.0327 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| China Shineway Pharmaceutical Group Ltd | 4.63bn | 1.22bn | 6.50bn | 3.44k | 4.88 | 0.8051 | 4.67 | 1.40 | 1.61 | 1.61 | 6.13 | 9.76 | 0.4476 | 1.28 | 5.26 | 1,346,646.00 | 11.76 | 8.03 | 15.47 | 9.77 | 75.21 | 74.55 | 26.27 | 17.87 | 3.14 | -- | 0.0457 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.10bn | 1.81bn | 7.21bn | 4.89k | 3.97 | 0.7558 | 3.42 | 1.18 | 2.06 | 2.06 | 6.93 | 10.84 | 0.4272 | 2.50 | 3.57 | 1,320,291.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 25.51 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Everest Medicines Ltd | 460.62m | -1.16bn | 7.45bn | 520.00 | -- | 1.51 | -- | 16.17 | -3.60 | -3.60 | 1.43 | 15.13 | 0.0756 | 5.23 | 3.22 | 1,066,239.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Cansino Biologics Inc | 670.77m | -953.77m | 7.84bn | 1.49k | -- | 0.8896 | -- | 11.69 | -3.86 | -3.86 | 2.72 | 22.54 | 0.0676 | 1.28 | 0.8385 | 448,974.00 | -10.15 | -4.27 | -13.73 | -5.60 | 14.38 | -- | -150.19 | -27.72 | 2.19 | -- | 0.3028 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Luye Pharma Group Ltd | 6.95bn | 847.89m | 11.36bn | 5.27k | 13.40 | 0.7929 | 6.66 | 1.64 | 0.2254 | 0.2254 | 1.85 | 3.81 | 0.236 | 2.44 | 2.84 | 1,318,408.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 2.96 | 0.4016 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 11.39bn | 5.80k | 8.36 | 1.57 | 6.23 | 1.76 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Shanghai Henlius Biotech Inc | 6.21bn | 761.91m | 12.58bn | 3.55k | 16.55 | 4.43 | 10.77 | 2.03 | 1.40 | 1.40 | 11.37 | 5.22 | 0.5764 | 1.90 | 6.82 | 1,706,729.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 6.86 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| 3SBio Inc | 9.27bn | 1.83bn | 13.49bn | 5.61k | 7.51 | 0.8452 | 5.96 | 1.46 | 0.7493 | 0.7493 | 3.80 | 6.66 | 0.3575 | 1.52 | 6.73 | 1,712,778.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 23.87 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 15.05bn | 10.78k | 6.16 | 0.9575 | 5.23 | 1.42 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 3.21 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| The United Laboratories Intl. Hldgs Ltd. | 15.42bn | 3.20bn | 15.24bn | 15.00k | 4.76 | 1.02 | 3.99 | 0.9888 | 1.76 | 1.76 | 8.48 | 8.19 | 0.6578 | 3.30 | 3.54 | 1,027,797.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Simcere Pharmaceutical Group Ltd | 6.98bn | -1.21bn | 15.69bn | 7.03k | -- | 2.14 | -- | 2.25 | -0.4638 | -0.4638 | 2.71 | 2.91 | 0.5198 | 2.19 | 2.64 | 993,214.30 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4709 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Zai Lab Ltd | 2.51bn | -2.32bn | 16.28bn | 2.18k | -- | 2.92 | -- | 6.47 | -2.39 | -2.39 | 2.59 | 5.59 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
Data as of Sep 20 2024. Currency figures normalised to SSY Group Ltd's reporting currency: Hong Kong Dollar HKD
16.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management (Hong Kong) Ltd.as of 31 Jul 2024 | 218.06m | 7.35% |
| UBS SDIC Fund Management Co., Ltd.as of 08 Mar 2024 | 61.15m | 2.06% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 53.52m | 1.80% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 35.59m | 1.20% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 28.58m | 0.96% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 22.18m | 0.75% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 21.43m | 0.72% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 17.85m | 0.60% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 17.84m | 0.60% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 16.97m | 0.57% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
